GSK forges novel R&D partnerships with CDRD

Guest Contributor
June 4, 2012

GlaxoSmithKline (GSK) has entered into a two-part R&D collaboration with the Centre for Drug Research and Development (CDRD) and its commercial arm CDRD Ventures Inc (CVI). The novel agreement will see GSK support early-stage projects through CDRD via the GSK-CDRD Innovation Fund. These projects will engage academic investigators at CDRD's affiliated institutions or hospital-based research centres. Another fund in conjunction with CVI will move later-stage projects further toward commercialization. GSK will partially fund projects conducted or managed by CVI. The GSK collaboration is the latest industry partnership forged by CDRD. It also has deals with Roche, Pfizer Canada and Johnson & Johnson (US) (R$, February 27/12)….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.